BRAF and cancer: Our work suggests that, at least in part, therapeutic response may be explained by the expression levels of mRNA for BRAF and the degree of activation of the MAPK pathway and resistance genes in the presence of the BRAF V600E mutant, and that this may be context-dependent based on the type of cancer.